Novartis

STAT Plus: Pharmalittle: FDA plans ‘concierge service’ for expanded access to cancer meds; Novartis ‘anchored’ gene therapy price

Top of the morning to you, and a fine one it is. A shiny sun and crisp breeze are enveloping the Pharmalot campus, where the short people have left for...

Read more
STAT Plus: Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t

A pretty impressive result from ASCO that’s also being published in the New England Journal of Medicine: Kisqali, a breast cancer drug from Novartis (NVS), dramatically extended survival in younger...

Read more
STAT Plus: Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy

CAMBRIDGE, Mass. — Days before his company is expected to win approval of the most expensive drug ever, the head of Swiss drug giant Novartis said Wednesday he could justify...

Read more
At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug

The Food and Drug Administration on Friday approved the first gene therapy for a type of spinal muscular atrophy, a lifesaving treatment for infants that will also be the most...

Read more
STAT Plus: Pharmalittle: Novartis to price gene therapy ‘far lower’ than $4m; advocates press WHA on transparency resolution

Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that rain clouds have departed and the sun is trying mightily to warm...

Read more
STAT Plus: Pharmalittle: Lawmakers push bill to punish opioid execs; Novartis will have ‘enormous leverage’ pricing its SMA drug

Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that the middle of the week is here. After all, this means just...

Read more
STAT Plus: Pharmalittle: Pfizer prices new rare disease drug at $225,000; Novartis pushes gene therapy

[ad_1] Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so-familiar routine of meetings, deadlines, and conference calls has predictably...

Read more
STAT Plus: Launching a new gene therapy will be the biggest test yet for Novartis CEO Narasimhan

[ad_1] At the start of his second year on the job, Novartis CEO Vas Narasimhan is about to face his biggest test yet: the launch of a breakthrough gene therapy...

Read more
New patent expiration for Novartis Pharms drug PROMACTA KIT

Annual Drug Patent Expirations for PROMACTA+KIT Promacta Kit is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are…...

Read more
STAT Plus: Pharmalittle: Novartis probes second death in gene therapy trial; FDA approves generic Narcan

[ad_1] Good morning, everyone, and welcome to another working week. We hope the weekend respite, which was an extended treat for some, was relaxing and invigorating, because that oh-so-familiar routine...

Read more
New patent expiration for Novartis Pharms drug JADENU SPRINKLE

Annual Drug Patent Expirations for JADENU+SPRINKLE Jadenu Sprinkle is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There is…...

Read more
New patent expiration for Novartis Pharms drug JADENU

Annual Drug Patent Expirations for JADENU Jadenu is a drug marketed by Novartis Pharms Corp and is included in two NDAs. It is available from one supplier. There are two…...

Read more
Novartis acquires IFM Therapeutics subsidiary for $310 million

[ad_1] Novartis on Monday announced it has acquired the full rights to several of IFM Tre’s research assets, which consists of one clinical and two pre-clinical programs, for a minimum...

Read more
Novartis in nearly $1.6B deal to buy NASH-focused subsidiary of IFM Therapeutics

[ad_1] The deal includes a $310 million upfront payment plus milestones for three IFM Tre assets – one clinical drug for NASH and atherosclerosis and two preclinical molecules. Source link...

Read more
STAT Plus: Pharmalittle: Novartis strikes an immunotherapy deal; China to regulate all fentanyl-related drugs

[ad_1] Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, conferences, and Skype calls...

Read more
Novartis acquires Boston-based IFM Tre for work on drugs to modify the immune system

[ad_1] It’s the lucky biotech that has a short and sweet runway. Most companies bring a drug to market — and begin to bring in revenue — only after years...

Read more
STAT Plus: Pharmalittle: Gilead and CDC tussle over Truvada patents; Novartis wins FDA approval for an MS drug

[ad_1] Top of the morning to you. The middle of the week is upon us and, since you made it this far, why not forge ahead? After all, there is...

Read more
Novartis launches COPD inhalers in China

[ad_1] Novartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease. The Ultibro Breezhaler system is a once-daily fixed-dose combination of...

Read more
Novartis plans Alcon spinout for early April

[ad_1] Novartis (NYSE:NVS) said today that it’s planning to list the shares of its Alcon vision care business April 9 in Switzerland and New York. Terms for the spinout, announced...

Read more
STAT Plus: Pharmalittle: Pfizer pays $636 million for rights to gene therapies; Novartis denies bribing Greek officials

[ad_1] Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves....

Read more